TriSalus Life Sciences, Inc. (TLSI) stock
Close on Nov 18, 2026Market cap $150.86MP/E –Yield –
Earnings
TriSalus Life Sciences's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of TriSalus Life Sciences's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Mar 4, 2027Expected | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Nov 10, 2026before the open | $12.90M | +11.2% | -$0.15 | Release |
| Q2 FY2026ended Jun 30, 2026 | Aug 6, 2026after the close | $11.40M | +1.8% | -$0.16 | Release |
| Q1 FY2026ended Mar 31, 2026 | May 12, 2026after the close | $8.90M | -3.3% | $0.03 | Release |
| Q4 FY2025ended Dec 31, 2025 | Mar 5, 2026after the close | $13.20M | +59.0% | -$0.21 | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 13, 2025after the close | $11.60M | +58.9% | -$0.96 | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 12, 2025after the close | $11.20M | +51.4% | -$0.27 | Release |
| Q1 FY2025ended Mar 31, 2025 | May 15, 2025before the open | $9.20M | +41.5% | -$0.39 | Release |
| Q4 FY2024ended Dec 31, 2024 | Mar 27, 2025before the open | $8.30M | – | -$0.40 | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 14, 2024before the open | $7.30M | +40.4% | -$0.12 | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 15, 2024before the open | $7.40M | – | -$0.21 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 15, 2024before the open | $6.50M | – | -$0.60 | Release |
| Q4 FY2023ended Dec 31, 2023 | Mar 12, 2024after the close | – | – | – | Filing |
| Q3 FY2023ended Sep 30, 2023 | Nov 14, 2023before the open | $5.20M | – | -$0.13 | Release |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
TriSalus Life Sciences's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| full-year 2026 revenue guidance | FY2026 | $54.00M – $57.00M | $54.00M – $57.00M | Reaffirmed | Aug 6, 2026 |
| growth | FY2026 | +19% – +26% | – | New | Aug 6, 2026 |
| revenue guidance | FY2026 | $46.00M – $48.00M | $60.00M – $62.00M | Lowered | Nov 10, 2026 |
Guidance vs results
The last range TriSalus Life Sciences gave before each report, against the figure it then reported. Full years add up the four quarters.
| Period | Metric | Guidance | Actual | Result |
|---|---|---|---|---|
| FY2025 | Revenue growth | +50% | +53.22%Σ4Q | Above range |
Guidance history
Every forecast TriSalus Life Sciences put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Nov 10, 2026 | revenue guidance | FY2026 | $46.00M – $48.00M | Lowered |
| Aug 6, 2026 | growth | FY2026 | +19% – +26% | New |
| Aug 6, 2026 | full-year 2026 revenue guidance | FY2026 | $54.00M – $57.00M | Reaffirmed |
| May 12, 2026 | revenue guidance | FY2026 | $54.00M – $57.00M | Lowered |
| Mar 5, 2026 | revenues | FY2026 | $60.00M – $62.00M | New |
| Jan 12, 2026 | full-year revenues | FY2026 | $60.00M – $62.00M | New |
| Nov 13, 2025 | full-year revenue growth | FY2025 | +50% | New |
| Aug 12, 2025 | revenue growth | FY2025 | +50% | Reaffirmed |
| May 15, 2025 | revenue | FY2025 | +50% | Reaffirmed |
| Mar 27, 2025 | Gross margins | FY2025 | 87% | New |
| Mar 27, 2025 | Operating expenses | FY2025 | +20% | New |
| Mar 27, 2025 | Sales | FY2025 | +50% | Reaffirmed |
| Jan 23, 2025 | revenue | FY2025 | +50% | Reaffirmed |
| Nov 14, 2024 | reduction in operating expenses | FY2025 | 20% | New |
| Nov 14, 2024 | sales growth | FY2025 | +50% | New |
| May 15, 2024 | sales growth | FY2024 | +50% | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases TriSalus Life Sciences filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- News
- Results
- Results
- Update
- Results
- News
- News
- Update
- Results
- Results
- Results
- News
- News
- News
See a number that looks wrong?